CN112912396A - 抗cldn18.2抗体及其用途 - Google Patents

抗cldn18.2抗体及其用途 Download PDF

Info

Publication number
CN112912396A
CN112912396A CN201880098896.8A CN201880098896A CN112912396A CN 112912396 A CN112912396 A CN 112912396A CN 201880098896 A CN201880098896 A CN 201880098896A CN 112912396 A CN112912396 A CN 112912396A
Authority
CN
China
Prior art keywords
sequence
seq
substitution
antibody
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880098896.8A
Other languages
English (en)
Other versions
CN112912396B (zh
Inventor
杜靓
张红艳
凌文
袁纪军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jibei Biotechnology Co ltd
Original Assignee
Shanghai Jibei Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jibei Biotechnology Co ltd filed Critical Shanghai Jibei Biotechnology Co ltd
Publication of CN112912396A publication Critical patent/CN112912396A/zh
Application granted granted Critical
Publication of CN112912396B publication Critical patent/CN112912396B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供一种抗CLDN18.2的抗体或其抗原结合片段，编码其的核酸分子，包含其的免疫缀合物、双特异性分子、嵌合抗原受体及药物组合物，所述抗体或抗原结合片段用于预防和/或治疗肿瘤。

Description

PCT国内申请，说明书已公开。

Claims (47)

  1. PCT国内申请，权利要求书已公开。
CN201880098896.8A 2018-10-22 2018-10-22 抗cldn18.2抗体及其用途 Active CN112912396B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/111201 WO2020082209A1 (zh) 2018-10-22 2018-10-22 抗cldn18.2抗体及其用途

Publications (2)

Publication Number Publication Date
CN112912396A true CN112912396A (zh) 2021-06-04
CN112912396B CN112912396B (zh) 2023-03-14

Family

ID=70330841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880098896.8A Active CN112912396B (zh) 2018-10-22 2018-10-22 抗cldn18.2抗体及其用途

Country Status (11)

Country Link
US (1) US20210403552A1 (zh)
EP (1) EP3872093A4 (zh)
JP (1) JP7401538B2 (zh)
KR (1) KR20210093879A (zh)
CN (1) CN112912396B (zh)
AU (1) AU2018447127A1 (zh)
BR (1) BR112021007690A2 (zh)
CA (1) CA3117240A1 (zh)
MX (1) MX2021004588A (zh)
WO (1) WO2020082209A1 (zh)
ZA (1) ZA202103061B (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023020537A1 (zh) * 2021-08-18 2023-02-23 普米斯生物技术(珠海)有限公司 一种双特异性抗体及其用途
WO2023226836A1 (zh) * 2022-05-27 2023-11-30 苏州易慕峰生物科技有限公司 包含cldn18.2单域抗体的嵌合抗原受体及其应用
WO2024067612A1 (zh) * 2022-09-29 2024-04-04 南京博望医药科技有限公司 抗密蛋白18.2的抗体

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160560A2 (en) 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
TW202212360A (zh) * 2020-05-25 2022-04-01 中國大陸商蘇州創勝醫藥集團有限公司 抗ｃｌｄｎ１８．２抗體及其診斷用途
WO2022081971A1 (en) * 2020-10-16 2022-04-21 The Children's Medical Center Corporation Notch4 antibodies and uses thereof
JP2023550998A (ja) * 2020-11-27 2023-12-06 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｃｌｄｎ１８．２抗体及びその使用
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
JP2024500242A (ja) 2020-12-23 2024-01-05 ソティオ バイオテック エイ．エス． 腫瘍特異的クローディン１８．２抗体と薬物との複合体
US20240269315A1 (en) 2021-06-02 2024-08-15 Bio-Thera Solutions, Ltd. Drug conjugate and use thereof
CN117897403A (zh) * 2021-09-24 2024-04-16 盛禾(中国)生物制药有限公司 一种抗Claudin18.2抗体及其应用
CN115991784A (zh) * 2021-10-19 2023-04-21 宝船生物医药科技(上海)有限公司 抗cd47-cldn18.2双特异性抗体及其用途
CN117229415A (zh) * 2022-12-30 2023-12-15 邦恩泰(山东)生物医药科技集团股份有限公司 一种靶向Claudin18.2的嵌合抗原受体、CAR-T细胞及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102341412A (zh) * 2009-03-05 2012-02-01 梅达莱克斯公司 特异于cadm1 的全人抗体
CN107667118A (zh) * 2015-04-15 2018-02-06 加尼梅德药物有限公司 包含针对密封蛋白18.2之抗体的药物缀合物
CN107960056A (zh) * 2015-05-11 2018-04-24 拜恩科技细胞&基因治疗有限公司 闭合蛋白-18.2特异性免疫受体和t细胞表位
CN108472349A (zh) * 2016-06-23 2018-08-31 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
SG190997A1 (en) 2010-12-09 2013-07-31 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102341412A (zh) * 2009-03-05 2012-02-01 梅达莱克斯公司 特异于cadm1 的全人抗体
CN107667118A (zh) * 2015-04-15 2018-02-06 加尼梅德药物有限公司 包含针对密封蛋白18.2之抗体的药物缀合物
CN107960056A (zh) * 2015-05-11 2018-04-24 拜恩科技细胞&基因治疗有限公司 闭合蛋白-18.2特异性免疫受体和t细胞表位
CN108472349A (zh) * 2016-06-23 2018-08-31 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023020537A1 (zh) * 2021-08-18 2023-02-23 普米斯生物技术(珠海)有限公司 一种双特异性抗体及其用途
WO2023226836A1 (zh) * 2022-05-27 2023-11-30 苏州易慕峰生物科技有限公司 包含cldn18.2单域抗体的嵌合抗原受体及其应用
CN117279949A (zh) * 2022-05-27 2023-12-22 苏州易慕峰生物科技有限公司 包含cldn18.2单域抗体的嵌合抗原受体及其应用
WO2024067612A1 (zh) * 2022-09-29 2024-04-04 南京博望医药科技有限公司 抗密蛋白18.2的抗体

Also Published As

Publication number Publication date
EP3872093A4 (en) 2022-10-19
KR20210093879A (ko) 2021-07-28
JP7401538B2 (ja) 2023-12-19
AU2018447127A1 (en) 2021-05-27
ZA202103061B (en) 2022-10-26
MX2021004588A (es) 2022-01-18
EP3872093A1 (en) 2021-09-01
WO2020082209A8 (zh) 2022-01-06
WO2020082209A1 (zh) 2020-04-30
US20210403552A1 (en) 2021-12-30
CA3117240A1 (en) 2020-04-30
CN112912396B (zh) 2023-03-14
JP2022516826A (ja) 2022-03-03
BR112021007690A2 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
CN112912396B (zh) 抗cldn18.2抗体及其用途
US20230192840A1 (en) Antibody and use thereof
US20190367612A1 (en) Anti-gprc5d antibody and molecule containing same
TWI564306B (zh) 雙特異性抗體
CN112912397A (zh) 抗cd3抗体及其用途
US20230312739A1 (en) Anti-cd73 antibody and use thereof
US11639388B2 (en) CD3 antigen binding fragment and application thereof
CN110734493B (zh) 抗pd-1抗体及其用途
US20190359712A1 (en) Anti-cd3 antibody and molecules comprising the antibody
TW202016143A (zh) 全人源的抗ｌａｇ－３抗體及其應用
CN115715297A (zh) 抗flt3抗体和组合物
AU2021395129A1 (en) Cd73 antigen-binding protein and application thereof
CN116568811A (zh) 结合cd73的蛋白及其应用
CN114340668A (zh) 结合于cd38和cd3的异源二聚抗体
WO2022183502A1 (zh) 抗cldn6抗体及其用途
TW202313699A (zh) 新型抗ｓｉｒｐａ抗體
KR20230135045A (ko) 항-cldn18.2 항체, 약물 결합체 및 이의 제조 방법 및 용도
RU2797709C2 (ru) Антитело к cldn18.2 и его применения
TW202140551A (zh) 抗cldn18.2抗體及其用途
WO2024000259A1 (zh) Cd22特异性结合抗体及其制备方法和其在双特异cart上的用途
US20230374132A1 (en) Anti-cd3 antibody and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044791

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant